Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05120934 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
A Phase 2 study of Interstitial Lung Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05120934: Recruiting Phase 2 study of Interstitial Lung Disease, sponsored by Mayo Clinic.
NCT05120934 is a Phase 2 study of Interstitial Lung Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 25 participants, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05120934, a Phase 2 study of Interstitial Lung Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.
Primary Outcome
The primary objective is to evaluate awake cough frequency at 4 and 8 weeks using the Leicester Cough Monitor. The acoustic cough monitor recordings will be analyzed using the Leicester Cough Monitor program V2.3-MB. This will also be performed at months 4, 6, 9 \& 12 for subjects who choose to continue with the optional unblinded continuation of the study after the initial 8 weeks.
Conditions Studied
Interventions
- DRUG Duloxetine 30 MG
- DRUG Amitriptyline 25 MG
- DRUG Amitriptyline 50 MG
- DRUG Duloxetine 60 MG
- DRUG Placebo 30 MG
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What NCT05120934 shows while recruiting
NCT05120934 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Interstitial Lung Disease appearing as the primary indexed condition, and to 5 interventions - of which Duloxetine 30 MG is the first listed.
NCT05120934 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05120934 about?
NCT05120934 is a clinical study titled "Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough". This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.
What is the current status of trial NCT05120934?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-11-01. Estimated completion is 2026-10.
What conditions does trial NCT05120934 study?
This clinical trial studies the following conditions: Interstitial Lung Disease.
What interventions are being tested in trial NCT05120934?
The interventions under investigation include: Duloxetine 30 MG (DRUG), Amitriptyline 25 MG (DRUG), Amitriptyline 50 MG (DRUG), Duloxetine 60 MG (DRUG), Placebo 30 MG (DRUG).
Who is sponsoring clinical trial NCT05120934?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05120934 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05120934's enrollment target sits among peer trials
25 31st of 36 higher than 4 of 36 other Interstitial Lung Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Lung Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI